Bölüm
38

OKÜLER MELANOMDA GÜNCEL YAKLAŞIM

Adil ÖZYILKAN[1]
Hüseyin MERTSOYLU

GİRİŞ

Oküler melanom cilt melanomlarından sonra en sıklıkla görülen ikinci melanomlardır.Ayni zamanda göz kanserlerinde ise en sık görülen malign tümördür.Melanomlar gözde melanositlerin oldukları yerde olurlar ve en sık üvea da oluşur.Üvea dışta sklera içte retina arasında olan iris,corpus siliyare ve choroidi içeren yapıdır. Oküler melanomların %82.5 uvea da oluşmakta olup konjonktival melanomlar daha az sıklıkta görülür .Ocular melonomlar genellikle primer olup metastatik melanomlar ise orbita ve gözlerdeki tümörlerden %5 ni oluşturur.

EPİDEMİOLOJİ

Oküler melanom milyonda 6 ,cilt melanomu ise 153.5 görülür(1).Amerika ve Avusturalyada yapılan çalışmalarda Oküler melanom erkek/kadın oranı 1.29 olarak bulunmuştur.

Konjonktival melanom milyonda 0.4 görülürken üveal melanom 4.9 görülmüştür(1).Avrupada melanom incidansı kuzey güney arası farklılık gösterip güneyde milyonda 8 kuzeyde 2 nin altına kadar düşmektedir.(2a)

Oküler melanom oranları siyahlar ile karşılaştırıldığında beyazlar arasında 8-10 kat daha yüksektir.Diğer oküler maelanımların aksine konjonktival melanom oranları siyahlara göre 2.6 kat daha fazladır.(3)Okular melanom insidansı yaşla birlikte artar yedinci sekizinci dekatta en yüksek seviyeye ulaşır.60 yaş üstü beyaz erkeklerde konjonktiva melanom riski artmaktadır

[1] Lefkoşa Dar. Burhan Nalbantoğlu Devlet Hastanesi Göz Hastalıkları Kliniği, Lefkoşa,Kuzuy Kıbrıs Türk Cumhuriyeti

KAYNAKLAR

1. McLaughlin CC,Wu XC,Jemal A,Martin HJ,Roche LM,Chen VW..Incıdence of noncutaneous melanomas in the U.S.Canser 2005;103:1000-7
2. Virgili G,Gatta G,Ciccolallo L,Capocaccia R,Biggeri A,Crocetti E, Lutz JM, Paci E ;EUROCA-RE working Group.Incidence of uveal melanoma in Europe .Ophthalmology 2007;114:2309-15
3. Shields CL, Furuta M. Thangappan A, Nagori S, Mashayekhi A, Lally DR, Kelly CC, Rudich DS, Nagori AV, Wakade OA, Mehta S, Forte L, Long A, Dellacava EF, Kaplan B, Shields JA, Metastasisof uveal melanoma millimeter-by-millimeter in 8033 consecutive eyes. Arch, Ophthalmol 2009;127;989-98.
4. Hu DN , Yu G ,McCormick SA, Finger PT.Population-based incidence of conjunktival melanoma in various races and ethnic groups and comparison with other melanomas .Am J Ophthalmol 2008 ;145:418-423.
5. Singh AD,De Potter P ,Fijal BA,Shields CL,Shields JA,Elston RC.Lıfetıme prevalence of uveal melanoma ın white patients with oculo (dermal)melanocytosis.Ophthalmology 1998;105:195-8.
6. Singh AD,Kalyani P Topham A.Estimatingthe rısk of malignant transformation of a choroıdal nevus.Ophthalmology 2005;112;1784-9.
7. Li HK,Shıelds CL,Mashayekhi A,Randolph JD,Bailey T,Burnbaum J,Shields JA,Giant choroıdal nevus clinical features natural course in 322 cases.Ophthalmology 2010 ;117:324-33
8. Kanski Clinical Ophthalmolgy Second edition
9. Conway RM,Chua WC, Qureshi C, Billson FA, Primary iris melanoma :diagnostic features and outcome of conservative surgical treatment.Br J ophthalmol 2007;85:848-54
10. Shields CL, Shields JA, Materin M, Gershenbaum E, Singh AD, Smith A, İris melanoma, : risk factors for metastasis in 169 consecutive patients, Ophthalmology 2001;108;172-8.
11. Shields CL, Naseripour M, Shields JA, Freire J, Cater J, Custom-designed, plaque radiotherapy for nonresectable iris melanoma in 38 patients; tumor control and ocular complications. Am J Ophthalmol 2003; 135; 648-56.
12. Diener-West M, Earle JD, Fine SL, Hawkins BS, Moy CS, Reynolds SM, Schachat AP, Straatsma BR; Collaborative Ocular Melanoma study Group The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma, III: initial mortality findings, COMS Report No. 18 Arch Ophthalmol 2001; 119; 969-82.
13. Collaborative Ocular Melanoma Study Group. The COMS Randomized trial of iodine 125 brachytherapy for choroidal melanoma: V. Twelve-year mortality rates and prognostic factors; COMS report No. 28. Arch Ophthalmol 2006; 124; 1684-93
14. Hawkins BS; Collaborative Ocular Melanoma Study Group. The Collaborative Ocular Mealonma Study (COMS) randomized trial of preenucleation radiation of large choroidal melanoma; IV. Ten-year mortality findings and prognostic factors. COMS report number 24.Am, J Ophthalmol 2004; 138; 936-51.
15. Augsburger JJ. İs observation really appropriate for small choroidal melanomas. Trans Am Ophthalmol Soc 1993;91;147-175.
16. Robertson Dm, Changing concepts in tha management of choroidal melanoma. Am J Ophthalmol 2003;136;161-70.
17. The Collaborative Ocular Melanoma study Group Factors predictive of growth and treatment of small choroidal melanoma; COMS Report No.5. Arch Ophthalmol 1997; 115; 1537-44.
18. Kroll S, Char DH, Qulvey J Castro J. A comparison of cause –specific melanoma mortality and all-cause mortality in survival analyses after radiation treatment for uveal melanoma , Ophthalmology 1998;105; 2035-45.
19. Kujala E, Makitie T, Kivela T, Very long-term prognosis of patients with malignant uveal melanoma. Invest Ophthalmol Vis Sci 2003;44;4651-9.
20. Collaborative Ocular Melanoma Study Group Assessment of metastatic disease status at death in 435 patients with large choroidal melanoma in the Collaborative Ocular Melanoma Study

(COMS) ; COMS report no. 15. Arch Ophthalmol 2001; 119; 670-6.
21. Dithmar S, Diaz CE, Grossniklaus HE. İntraocular melanoma spread to regional Iymph nodes; report of two cases. Retina 2000;20;76-9.
22. Diener-West M, Reynolds SM, Agugliaro DJ, Caldwell R, Cumming K, Earle JD Hawkins BS, Hayman JA , Jalyesimi, I Jampol LM , Kirkwood JM, Koh WJ, Robertson DM, Shaw JM, Straatsma BR, Thoma J; Collaborative Ocular Melanoma study Group, Development of metastatic disease after enrollment in the COMS trials for treatment of choroidal melanoma ; Collaborative Ocular Melanoma Study Group Report No. 26 Arch Ophthalmol 2005 ; 123; 1639-43.
23. Prescher G, :Bornfeld N, Hirche H, Horsthemke B, Jöckel KH, Becher R, Prognostic implications of monosomy 3 in uveal melanoma. Lancet 1996;347;1222-5.
24. Sisley K, Rennie IG, Parsons MA, Jacques R, Hammond DW, Bell SM, Potter AM, Rees RC. Abnormalities of chromosomes 3 and 8 in posterior uveal melanoma correlate with prognosis Genes Chromosomes Cancer 1997; 19; 22-8.
25. Aalto Y. Eriksson L. Seregard S. Larsson O. Knuutila S. Concomitant loss of chromosome 3 an whole arm losses and gains of chromosome 1,6,or 8 in metastasizing primary uveal melanoma Invest Ophthalmol Vis Sci 2001;42;313-7.
26. White VA, Cahambers JD, Courtright PD, Chang Wy, Horsman DE . Correlation of cytogeneticabnormalities with the outcome of patients with uveal melanoma . Cancer 1998;83;354-359
27. Kilic E, Naus NC, van Gils W, Klaver CC, van Til ME, Verbiest MM, Stijnen T, Mooy CM, Paridaens D, Beverloo HB, Luyten GP, de Klein A. Concurrent loss of chromosome arm 1p and chromosome 3 predicts a decreased disease-freesurvival in uveal melanoma patients . Ivest Ophthalmol Vis Sci 2005;46;2253-7.
28. Höglund M. Gisselsson D. Hansen GB, White VA, Sall T, Mitelman F, Horsman D. Dissecting Karyotpic patterns in malignant melanomas ; temporal clustering of losses and gains in melanoma karyotypic evolution . Int J Cancer 2004;108;57-65.
29. Onken MD, Worly LA, Harbour JW. A Metastasis modifier locus on human chromosome 8p in uveal melanoma identified by integrative genomic analysis Clin Cancer Res 2008;14;3737-45.
30. Parrella P, Sidransky D, Merbs SL, Allelotype of posterior uveal melanoma implications for a bifurcated tumor progression pathway . Cancer Res 1999;59;3032-7.
31. İsager P, Enghoim G, Overgaard J, Storm H, Uveal and conjunctival malignant melanoma in denmark 1943-97: observed and relative survival of patients followed through 2002. Ophthalmic Epidemiol 2006;13:85-96.
32. Shields CL, Shields JA, Gündüz K, Cater J, Mercado GV, Groos N, Lally B, Conjunctival melanoma, risk factors for recurrence, exentera tion, metastasis, and death in 150 consecutive patients Arch Ophthalmol 2000;118:1497-507.
33. Tuomaala S, Eskelin S, Tarkkanen A, Kivela T, Population –bassed assessment of clinical characteristics predicting outcome of conjunctival melanoma in whites. İnvest Ophthalmol Vis Sci 2002; 43:3399-408
34. Missotten GS , Keijser S. De Keizer RJ, De Wolff-Rouendaal D. Conjunctival melanoma in the Netherlands; a nationwide study. İnvest Ophthalmol Vis Sci 2005;46;75-82
35. Paridaens AD, McCartney AC, Minassian DC, Hungerford JL Orbital exenteration in 95 cases of primary conjun ctival malignant melanoma. Br J Ophthalmol 1994;78:520-8.
36. Lim M. Tatla T, Hersh D, Hungerford J. Patterns of regional head and neck lymph node metastasis in primary conjunctival malignant melanoma. Br J Ophthalmol 2006;90:1468-71.
37. Davies H, Bigneli GR, Cox C, Stephens P, Edkins, S, Teague J, Woffendin H,Garnett MJ, Bottomley W, Davis N, Dicks E, Ewingn R, Floyd Y, Gray K, ::Hall S, Hawes R, Hughes, J Kosmidou V, Menzies A, Mould C, Parker A, Stevens C, Watt, S, Wilson R, Jayatilake H, Gusterson BA, Cooper C, Shipley J, Hargrave D, Pritchard-Jones K, Maitland N, Chenevix Trench G, Riggins GJ, Bigner DD, Palmieri G, Cossu A, Flanagan A, Nicholson A, Ho JW, Leung SY, Yuen ST, Weber BL, Seigler HF, Darrow T, Paterson H, Marais R, Marshall CJ, wooster R, Stratton MR, Futreal PA, Mutations of the BRAF gene in human cancer. Nature 2002;417:949-54.
38. Poynter, JN, Elder JT, Fullen DR, Nair RP, Soengas MS, Johnson TM, Redman B, Thomas NE,

Gruber SB, BRAF and NRAS mutations in melanoma and melanocytic nevi. Melanoma Res 2006;16:267-73.
39. Fecher LA, Amaravadi RK, Flaherty KT, The MAPK pathway in melanoma. Curr Opin Oncol 2008;20:183-9.
40. Zuidervaart W, van Nieuwpoort F, Stark M, Dijkman R. Packer L, Borgstein AM, Pavey S, vander Velden P, Out C, jager MJ, Hayward NK , Gruis NA , Activation of the MAPK patway is a common event in uveal melanomas although it rarely occurs through mutation of BRAF or RAS, Br J Cancer 2005;92:2032-8
41. Veber A, Hengge UR, Urbanik D, Markwart A, Mirmohammadsaegh A, Reichel, MB, Wittekind C. Wiedemann p, Tannapfel A, Absence of mutations of the BRAF gene and constitutive activation of extracellular-regulated kinase in malignant melanomas of the uvea. Lab Invest 2003;83: 177-6.
42. Cohen Y. Goldenberg-Cohen N, Parrella P. Chowers I. Merbs SL, Pe'er J. Sidransky D. Lack of BRAF mutation in primary uveal melanoma, Invest Ophthalmol Vis Sci 2003; 44 : 2876-8.
43. Van Raamsdonk CD, Bezrookove V. Green G, Bauer J, Gaugler L, O'Brien JM, Simpson EM, Barsh GS, Bastian BC. Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi. Nature 2009;457:599-602.
44. Van Raamsdonk CD, Griewank KG, Crosby MB, Garrido MC, Vemula, S, Wiesner T, Obenauf AC, Wackernagel W, Green G, Bouvier N, Sozen mm, Baimukanova G, Roy R Heguy A, Dolgalev ı, Khanin R, BusamK, Speicher MR, O'Brien J, Bastian BC, Mutations in GNA11 in uveal melanoma, N Engi J Med 2010;363; 2191-9.
45. Onken MD, Worley LA, Long MD, Duan S, Council ML, Bowcock AM, Harbour JW. Oncogenic mutations in GNAQ occur early in uveal melanoma. İnvest Ophthalmol Vis Sci 2008;49:5230-4
46. Dratviman-Storobinsky O, Cohen Y. Frenkel S, Pe'er J, Goldenberg –Cohen N. Lack of oncogenic GNAQ mutations in melanocytic lesions of the conjunctiva as compared to uveal melanoma. İnvest Ophthalmol Vis Sci 2010;51:6180-2.
47. Henriquez F, Janssen C. Kemp EG. Roberts F. The T1799A BRAF mutation is present in iris melanoma, Invest Ophthalmol Vis Sci 2007;48:4897-900.
48. Gear H Williams H. Kemp EG, Roberts F. BRAF mutations in conjunctival melanoma. Invest Ophthalmol Vis Sci 2004;45:2484-8.
49. Beadling C. Jacobson—Dunlop E, Hodi FS, Le C, Warrick A, Patterson, J, Town A. Hsrlow A. Cruz F 3rd, Azar S, Rubin BP, Muller S, West R, Heinrich MC, Corless CL. KIT gene mutations and copy number in melanoma subtypes. Clin Cancer Res 2008;14:6821-8.
50. Harbour JW. Onken MD. Roberson ED. Duan S. Cao L. Worley LA. Council ML. Matatall Ka, Helms C, Bowcock AM. Frequent mutation of BAP1 in metastasizing uveal melanomas. Science 2010;330:1410-3
51. Abdel-Rahman MH, Pilarski R, Cebulla CM, Massengill JB Christopher BN, Boru G, Hovland P, Davidorf FH, Germline, BAP1 mutation predisposes to uveal melanoma , lung adeno carcinoma, meningioma, and other caners. J med Genet 2011;48:856-9
52. Wiesner T, Obenauf AC, Mural R, Fried I, Grie wank KG, Ulz P, Windpassinger C, Wackernagel W, Loy S, Wolf I, Viale, A, Lash AE, Pirun M, Socci ND, Rütten A, Palmedo G, Abramson D, Offit K, Ott A, Becker JC, Cerroni L, Kutzner H, Bastian BC, Speicher MR. Germline mutations in BAP1 predispose to melanocytic tumors . Nat Genet 2011;43:1018-21.
53. Abdel-Rahman MH, Yang Y, Zhou XP, Craig EL, Davidorf FH, Eng C, High frequency of submi croscopic hemizygous deletion is a major mechanism of expression of PTEN in uveal melanoma. J Clin Oncol 2006;24:288-95
54. Saraiva VS, Caissie AL, Segal L, Edelstein C, Burnier MN, Jr. Immunohistochemical expression of phospho-Akt in uveal melanoma. Melanoma Res 2005;15:245-50
55. Triozzi PL, Eng C, Singh AD, Targeted therapy for uveal melanoma, Cancer Treat Rev 2008;84:247-58.
56. Patel M, Smyth E, Chapman PB, Wolchok JD, Schwartz GK, Abramson DH, Carvajal RD, Therapeutic implications of the emerging molecular biology of uveal melanoma. Clin Cancer Res 2011;17:2087-100.

57. Shields JA , Shields CL, Mashayekhi A,Marr BP, Benavides R,Thangappan A ,Phan L,Eagle RC Jr.Primary acquired melanosis of the conjunctiva:experince with 311 eyes Trans Am Ophthalmol Soc 2007;105:61-71;discussion 71-2
58. Singh AD,Turell ME,Topham AK,Uveal melanoma:trends in incidence,treatment,and survival. Ophthalmology 2011;118:1881-5.
59. Chang AE,Karnell LH,Menck HR. The National Cancer Data Base report on cutaneous and noncutaneous melanoma : a summary of 84,836 casas from the past decade . The American Cancer Sosiety .Canser 1998;83;1664-78
60. Leiter U,Meier Fschittek B, Garbe C.The natural course of cutaneous melanoma .J Surg Oncol2004;86:172-8.
61. van den Bosch T,Kiliç E,Paridaens D,de Klein A.Genetics of uveal melanoma and cutaneous melanoma :two of a kınd ? Dermatol Res Pract 2010;2010:360136.